期刊文献+

β-淀粉样蛋白真核表达质粒的构建及鉴定 被引量:1

Construction and identification of recombinant plasmid pcDNA3-β amyloid
下载PDF
导出
摘要 目的构建β-淀粉样蛋白真核表达质粒,为进一步开展老年性痴呆DNA疫苗的保护性研究打下基础。方法提取Tg2576转基因鼠基因组DNA,PCR扩增β-淀粉样蛋白(Aβ1-42)基因,用限制性内切酶KpnⅠ/XhoⅠ分别对扩增产物和真核表达质粒pcDNA3.1酶切,将目的基因定向克隆到pcDNA3.1载体上;对重组质粒进行双酶切初步鉴定后进行序列测定。结果特异扩增出Aβ1-42片段,大小为126bp,片段成功插入pcDNA3.1载体中。经双酶切及序列测定结果表明Aβ1-42目的基因正确重组入pcDNA3.1载体中。结论成功构建Aβ1-42真核表达质粒。 Objective To construct a mammalian expression plasmid pcDNA3.1-β amyloid (pcDNA3.1-Aβ1-42), and to lay a foundation for further studying the protective immunity of pcDNA3.1-Aβ1-42 as an AD, sDNA vaccine. Methods Isolation the genome DNA from Tg2576 mice and amplified by PCR. The gene and the plasmid pcDAN3.1 were digested with Kpn I and Xho I respectively, and the gene was cloned into the pcDNA3.1 directionally. The recombinant vector pcDNA3.1-Aβ1-42 was characterized by restriction enzymes digestion and sequencing identification. Results The destination gene, 126 bp long, was amplified by PCR distinctively and inserted successfully into the plasmid pcDNA3.1. Enzymes digestion and sequencing identification showed that Aβ1-42 recombined with pcDNA3.1 exactly. Conclusion The mammalian expression vector pcDNA3.1-Aβ1-42 is successfully constructed
出处 《解剖学研究》 CAS 2006年第1期18-19,32,共3页 Anatomy Research
基金 国家自然科学基金(30400512) 国家重点基础研究发展计划(973计划)(2006CB500700) 粤港关键领域重点突破项目(20054982210) 广东省自然科学资金重点项目(20013137) 广东省自然科学资金(04300218) 广东省社会发展项目(2005B10401047) 广州市科技计划项目(2004Z3-E0151 2005Z3-E4021)
关键词 Β-淀粉样蛋白 DNA重组 序列测定 Tg2576转基因鼠 Amyloid-β protein DNA recombinant Sequence identification Tg2576 mice
  • 相关文献

参考文献6

二级参考文献43

  • 1Schenk D, Barbour R, Dunn W, et al. Immunization with amyloidbeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse[J]. Nature, 1999, 400(6740): 173 - 177.
  • 2Arendash GW, Gordon MN, Diamond DM, et al. Behavioral assessment of Alzheimer' s transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition andspatial memory [ J]. DNA Cell Biol, 2001, (11): 737 -744.
  • 3Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the endof the beginning [J]. Nat Rev Neurosci, 2002, 3(10): 824 -828.
  • 4Ott G. The adjuvant MF59: the 1998 perspective, clinical, persormanceand mechanism of action [J]. Res immunol, 1998, 149:25 -27.
  • 5J Mclaurin R, Cecal ME, Kierstead, et al. Therapeutically effectiveantibodies against amyliod-β residues 4-10 and inhibit cytotoxity andfibrillogenesis [ J ]. Nat Med, 2002, 8 ( 11 ): 1263 - 1269.
  • 6Ott G, Barchfeld GL, Van Nest G, et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59 [J]. Vaccine, 1995, 13(16): 1557-1562.
  • 7Plduslo JF, Cunan GL. Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brainbarrier [J]. Neuroreport, 2001, 12(15): 3197-3200.
  • 8Dohart JC, Bales Kr, Gannon KS, et al. Immunizarion reverses memory deficits without reducing brain Aβ burden in Alzheimer' s diseasemodel [J]. Nat Neurosci, 2002, 5 (5): 452 -457.
  • 9Jams AR, Nicoll, David W, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report[J]. NatMed, 2003, 10: 1-5.
  • 10Hock C, Konietzko U, Papassotiropoulos A, et al.Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease[J] . Nature Medicine, 2002, 8(11): 1270-5.

共引文献50

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部